Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02908100 · ClinicalTrials.gov registry record · Phase 2
A Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
A Phase 2 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 2
- Development phase
- 260
- Enrollment target
NCT02908100 is a Phase 2 study that has completed, run by Genentech. The registered enrollment target is 260 participants.
The verdict
NCT02908100, a Phase 2 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 260 participants
- Enrollment target
Study Summary
This is a study to evaluate the safety and efficacy of GDC-0853 in combination with standard of care therapy in participants with moderate to severe active systemic lupus erythematosus (SLE).
Interventions
- DRUG Placebo
- DRUG GDC-0853
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2017-01-19 |
| Est. Completion | 2019-07-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02908100
The ClinicalTrials.gov registry entry for NCT02908100 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 260 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02908100 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02908100 about?
NCT02908100 is a clinical study titled "A Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus". This is a study to evaluate the safety and efficacy of GDC-0853 in combination with standard of care therapy in participants with moderate to severe active systemic lupus erythematosus (SLE).
What is the current status of trial NCT02908100?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 260 participants. The study started on 2017-01-19. Estimated completion is 2019-07-16.
What interventions are being tested in trial NCT02908100?
The interventions under investigation include: Placebo (DRUG), GDC-0853 (DRUG).
Who is sponsoring clinical trial NCT02908100?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.